Awakn Life Sciences Reports Strong Q2 2022 Results
Awakn delivered revenue growth of 34% in Q2 Awakn also announces closing of first tranche of private placement financing TORONTO, CANADA, Sept 15, 2022 – Awakn Life Sciences Corp. (NEO:…
---
News
Awakn Life Sciences Signs Drug Development Agreement with Catalent for Zydis® Technology (An Orally Disintegrating Tablet) to Conduct Feasibility Studies to Improve Differentiation of its MDMA Program
TORONTO, CANADA, Sept, 12 2022 – Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) (‘Awakn’), a revenue-generating biotechnology company researching, developing, and commercializing therapeutics to treat addiction with a near-term focus on…
Awakn Life Sciences Signs Agreement With A Leading Drug Development Company to Deepen IP Moat For Its Lead Program
Agreement Provides 12-Month Exclusive Period to Agree in-Licensing Deal for Proprietary Formulation of Ketamine TORONTO, CANADA, August 25, 2022 – Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) (‘Awakn’), a revenue-generating…
Awakn Life Sciences Signs Second Licensing Partnership Agreement and Expands Commercial Operations Into Canada
Licensing Partnership with Wellbeings® marks entry into Canadian addiction treatment and relapse prevention market TORONTO, CANADA, August 18, 2022 – Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) (‘Awakn’), a revenue-generating…
Awakn Life Sciences Expands Commercial Operations Into The U.S. – First Licensing Partnership Agreement With Revitalist 
Awakn enters the U.S. addiction treatment and relapse prevention market TORONTO, CANADA, August 15, 2022 – Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) (‘Awakn’), a revenue-generating biotechnology company researching, developing,…
Awakn Life Sciences’ Phase III Trial Approved For ~CA$2.5 Million Funding From UK State Covering 66% of Costs
Phase III Trial to Cost ~CA$3.75 million with Awakn’s contribution expected to be ~CA$1.25 million Marks First Psychedelic Phase III Trial Ever to Receive Government Funding TORONTO, CANADA, 20 July,…
Awakn Provides a Business & Corporate Update
TORONTO, CANADA, July 15, 2022 – Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) (‘Awakn’), a revenue-generating biotechnology company researching, developing, and commercializing therapeutics to treat addiction with a near-term focus on…
Awakn Receives UK State Funding to Identify Optimal Pathway to Market In UK & US For Its Lead Clinical Development Program – Ketamine-Assisted Therapy For Alcohol Use Disorder
Awakn Provides Business Update on Progressing its Lead Program from Phase II b to Phase III TORONTO, CANADA, July 05, 2022 – Awakn Life Sciences Corp. (NEO: AWKN, OTCQB: AWKNF, FSE:…
Awakn Life Sciences to Present In Upcoming June 2022 Conferences
TORONTO, CANADA, June 20, 2022 – Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) (‘Awakn’), a revenue-generating biotechnology company researching, developing, and commercializing therapeutics to treat addiction with a near-term…
Awakn Life Sciences Reports Results for Quarter Ended April 30, 2022
Awakn delivered revenue growth of 24% in the quarter TORONTO, CANADA, June 14, 2022 – Awakn Life Sciences Corp. (NEO: AWKN, OTCQB: AWKNF, FSE: 954) (‘Awakn’), a biotechnology company, researching, developing,…
Awakn Life Sciences Appoints Biotech and Investment Veteran Dennis Purcell as a Special Advisor to the CEO
Seasoned Leader Brings Deep Knowledge of US Biotech Market to Awakn TORONTO, CANADA, June 7, 2022 – Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) (‘Awakn’), a biotechnology company, researching, developing,…
Awakn Life Sciences Initiates Follow-on Behavioral Study to Focus on Gambling Disorder
Study Initiated Following Recent Successful Pilot Study and Patent Filing TORONTO, CANADA, June 2, 2022 – Awakn Life Sciences Corp. (NEO: AWKN, OTCQB: AWKNF, FSE: 954) (‘Awakn’), a biotechnology company, researching, developing,…
Sign Up for Newsletter
MAIN OFFICE
Awakn Life Sciences Corp
301-217 Queen St. W
Toronto, Ontario M5V 0R2
Canada
© 2023 Awakn Life Sciences Corp | Privacy Policy | Disclaimer
// ABOUT US SUB NAV
// THERAPEUTIC FOCUS SUB NAV
// R&D SUB NAV
